OXFORD BIOMEDICA (OXB): MODERATED CHART AND DISCUSSION THREAD

the_doctor (Post 15478) and gerry2 (Post 15483) recent statements from OXB appear to indicate that a deal for TroVax is imminent, as follows:

1) OXB, RNS: Positive Opinion on TroVax (8/12/2006):

"Oxford BioMedica has a key strategic objective of securing a major corporate
partner for the ongoing development and commercialisation of TroVax. The Company has progressed to negotiations of terms with its lead prospective partners and remains committed to finalising a deal expeditiously".



2) OXB, RNS: PIII Trial in TroVax (7/11/2006):

"...The Company remains committed to securing a major corporate partner for the ongoing development and commercialisation of TroVax. As reported in September, discussions with lead prospective partners have progressed to development strategies and deal terms. The most advanced prospect is a major pharmaceutical company with a leading oncology franchise that completed its due diligence on the TroVax programme recently. Oxford BioMedica is working expeditiously with three other global pharmaceutical companies to bring all four companies to the same stage of discussions..."



3) Interim Results (5/9/2006) and AFX (5/9/2006):

Interim Results: "...several major pharmaceutical and biotechnology companies are evaluating the program. The leading prospective partners are in advanced stages of due diligence and are assessing the commercial opportunity of TroVax in multiple cancer types. Discussions with these companies on development strategies and deal structures are ongoing...

...The Company remains committed to securing a suitable commercial partner for the ongoing development and commercialisation of TroVax..."


AFX: "...We're in good shape and still working toward our goal of getting (a deal) done this year," he [AK] said in an interview, declining to be more precise..."



4) Interim Results Presentation (5/9/2006):

Comment by CEO AK in accompanyment to Slides 15/16:

"We wanted to get a partner in place during this calender year and we're working hard towards that..."

Slide 15: Near Term Value Drivers include a "Commercial Partnership - Global Agreement" for TroVax, i.e. a deal.